PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Basit Öğe Kaydı
dc.authorscopusid56082620300
dc.authorscopusid57226431644
dc.authorscopusid57226624079
dc.authorscopusid57431169800
dc.authorscopusid54584820400
dc.authorscopusid57204201984
dc.authorscopusid57218910059
dc.contributor.authorAvcı, O.
dc.contributor.authorIriagaç, Y.
dc.contributor.authorÇavdar, E.
dc.contributor.authorKaraboyun, K.
dc.contributor.authorAraz, M.
dc.contributor.authorSakalar, T.
dc.contributor.authorDeğerli, E.
dc.date.accessioned2024-08-25T18:48:02Z
dc.date.available2024-08-25T18:48:02Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (?65 years) with metastatic breast cancer patients were investigated. Materials and Methods: Among older patients receiving palbociclib and ribociclib, Geriatric 8 (G8) and Groningen Frailty Index were used to evaluate frailty status. Dose modifications, drug withdrawal and other serious adverse events (SAEs) were recorded and analyzed according to baseline patient characteristics. Results: A total of 160 patients from 28 centers in Turkey were included (palbociclib = 76, ribociclib = 84). Forty-three patients were ? 75 years of age. The most common cause of first dose modification was neutropenia for both drugs (97% palbociclib, 69% ribociclib). Liver function tests elevation (10%) and renal function impairment (6%) were also causes for ribociclib dose modification. Drug withdrawal rate was 3.9% for palbociclib and 6% for ribociclib. SAEs were seen in 11.8% of those taking palbociclib and 15.5% of those on riboclib. An ECOG performance status of ?2 and being older than 75 years were associated with dose reductions. Severe neutropenia was more common in patients with non-bone-only metastatic disease, those receiving treatment third-line therapy or higher, coexistance of non-neutropenic hematological side effects (for ribociclib). Neutropenia was less common among patients with obesity. Discussion: Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged ?75 years and/or with an ECOG performance status ?2. © 2023 Elsevier Ltden_US
dc.identifier.doi10.1016/j.jgo.2023.101604
dc.identifier.issn1879-4068
dc.identifier.issue8en_US
dc.identifier.scopus2-s2.0-85169931836en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.jgo.2023.101604
dc.identifier.urihttps://hdl.handle.net/11454/102114
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofJournal of Geriatric Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAdverse eventsen_US
dc.subjectBreast canceren_US
dc.subjectCDK 4/6 inhibitorsen_US
dc.subjectGeriatricsen_US
dc.titlePROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu